𝔖 Bobbio Scriptorium
✦   LIBER   ✦

MHC restriction to T-cell autoaggression: an emerging understanding of IDDM pathogenesis

✍ Scribed by Choudhuri, K. ;Vergani, D.


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
166 KB
Volume
14
Category
Article
ISSN
0742-4221

No coin nor oath required. For personal study only.

✦ Synopsis


The Nobel prize-winning discovery of MHC restriction by Zinkernagel and Doherty has led to some of the most exciting advances in immunology over the past two decades. The ongoing progress in our conceptual understanding of the processes governing the immunology to infection, tolerance to self and consequently the immune dysregulation in autoimmunity have all assimilated the laws of restriction as a central tenet. The focus of much of this research has been the T-cell and its interactions. Refinement of the paradigm of MHC restriction at the molecular level has allowed a view of the pathogenesis of insulin-dependent diabetes mellitus (IDDM), a prototypic autoimmune disease, unprecedented in its detail. This article discusses the impact of MHC restriction on the central themes of immunology, and focuses on its utility as a framework in understanding the role of the T-cell in the pathogenesis of IDDM.


📜 SIMILAR VOLUMES


Efficient MHC Class II-restricted presen
✍ D. Gerlier; M.-C. Trescol-Biémont; G. Varior-Krishnan; D. Naniche; I. Fugier-Viv 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 297 KB

## ABSTRACT The role of the measles virus (MV) receptor, human CD46, in the uptake of MV and antigen presentation by Major Histocompatibility Complex (MHC) class II molecules was investigated. Expression of CD46 in murine B cells resulted in cells highly efficient in capturing UV‐inactivated MV par

Peptide-antibody conjugates for tumour t
✍ Zhiwei Yu; Frank Healy; Danila Valmori; Patricia Escobar; Giampietro Corradin; J 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 729 KB

Anti-idiotype antibody therapy of B-cell lymphomas, despite numerous promising experimental and clinical studies, has so far met with limited success. Tailor-made monoclonal antiidiotype antibodies have been injected into a large series of lymphoma patients, with a few impressive complete tumour rem